Levosimendan early treatment vs placebo for cardiogenic shock
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether giving levosimendan early (a heart-strengthening medicine) improves outcomes compared with placebo, on top of standard inotropic support, in people with cardiogenic shock. It mainly looks at whether patients have fewer serious complications or deaths.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and currently in cardiogenic shock
- Your blood pressure is being supported with medications like norepinephrine and/or dobutamine for 3 to under 24 hours
- You have signs that organs are not getting enough blood, such as high lactate, reduced urine, weak skin color refill, low oxygen in blood, or abnormal blood gas measures
- Your doctors think your blood volume is adequate (not dangerously dehydrated)
- You have not used levosimendan in the last 15 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug levosimendan, which helps the heart pump better during shock, works in the body of adults in the ICU. By measuring drug levels in the blood, researchers hope to find the best dosing for each person.
This early study looks at how well the heart is pumping in people with cardiogenic shock, using measurements taken during a right-heart catheter (a small pressure-monitoring test). It may help doctors better assess heart function and guide next-step treatments like LVAD, heart transplant, or valve surgery.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This study is testing a device called an intra-aortic balloon pump (a small balloon placed in your heart's main artery to help it pump) for people in the early stages of cardiogenic shock, a condition where the heart can't pump enough blood. The goal is to see if adding this supportive device early on improves outcomes for patients with heart attacks or other heart problems.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.